Search

Displaying results 4121 - 4130 of 10000 in total
  1. Drug

    Elacytarabine

    go.drugbank.com/drugs/DB05494
    Investigational

    Elacytarabine is a fatty acid derivative of [cytarabine], an approved cytotoxic cancer drug. Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia. … Elacytarabine is designed to overcome this limitation and has shown considerable uptake in solid tumour cells.

  2. Drug

    T-5224

    go.drugbank.com/drugs/DB05998
    Experimental

    T-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.

  3. Drug

    Chlorocresol

    go.drugbank.com/drugs/DB16864
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Hydrocortisone aceponate

    go.drugbank.com/drugs/DB14538
    InvestigationalVet approved

  5. Drug

    Thiacloprid

    go.drugbank.com/drugs/DB08620
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    SAR-260301

    go.drugbank.com/drugs/DB33608
    Investigational

    Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors
  7. Drug

    Trafermin

    go.drugbank.com/drugs/DB06244
    Investigational

  8. Drug

    KP-1461

    go.drugbank.com/drugs/DB05644
    Investigational

    KP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue.

  9. Drug

    NCX 1022

    go.drugbank.com/drugs/DB05410
    Experimental

    NCX is an NO-releasing derivative of hydrocortisone.

  10. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.